Navigation Links
Added benefit of dapagliflozin is not proven
Date:6/6/2013

Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. No such added benefit can be derived from the dossier, however, because the drug manufacturer did not present any relevant data for any of the possible therapeutic indications of dapagliflozin.

Monotherapy or combination therapy possible

Dapagliflozin is approved both as monotherapy and in combination with other blood-glucose lowering drugs, including insulin. As monotherapy it is an option for patients who do not tolerate metformin. Dapagliflozin can also be used as combination therapy, either together with metformin or with sulfonylureas if either of these two drugs alone is insufficient to control blood sugar. Dapagliflozin can also be combined with insulin if the target blood sugar levels cannot be achieved with insulin alone. Other combinations with oral antidiabetics are possible, but these were not presented by the manufacturer in its dossier.

G-BA specified appropriate comparator therapy

The Federal Joint Committee (G-BA) specified a sulfonylurea (glibenclamide or glimepiride) as appropriate comparator therapy for the dapagliflozin monotherapy. The combination therapy of dapagliflozin and metformin was also to be compared with one of these two drugs (each supplemented with metformin). The combination of dapagliflozin with a sulfonylurea was to be tested against metformin in combination with one of the sulfonylureas glibenclamide or glimepiride. According to the G-BA's specifications, the combination of dapagliflozin and insulin was to be compared either with human insulin and metformin, or, if metformin was
'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. The Newest Features Added to Dokmee
2. Aflibercept in AMD: No proof of added benefit
3. Hiring of New Sales Engineer Creates Added Value for Customers at Strouse
4. Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity
5. DrugRisks Update: Warning Added to Pradaxa For Blood Condition
6. Younger Men Biggest Consumers of Added Sugars: CDC
7. Finishing Touches Added as Hotel Shangrila Continues to Restore this Streamline Moderne Gem
8. Added benefit of saxagliptin/metformin combination is not proven
9. Left Coast Marijuana Delivery Service Added To Top-Tier Dispensary Locator
10. BPA Added To California’s Toxic Chemicals List Making BPA-Free Dental Products from PureLife More Attractive
11. Astro-Clairvoyant Norah Guide With Premium Astrology Extends Blog Series With Newly Added Video Features
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Yesterday, Senator Holly Mitchell (D-Los ... Olsen (R-Modesto) were honored by the California Healthcare ... biomedical science, medical device and pharmaceutical innovation in ... “2014 Life Sciences Champion” award from CHI President ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
(Date:1/22/2015)... 2015 Lower-Auto-Insurance.com has released a new blog post ... car for reducing the costs of an auto insurance policy ... able to get lower prices for their vehicle insurance policies. The ... in determining policy costs. Because of this, drivers should always ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... particles for treatment of diseases. ‘Nano’ refers to billionth ... for treatment of fatal diseases, which will help to ... to develop Nanotechnology in the next 10 years which ... diabetes, Cancer, HIV infection, Alzheimer’s and Parkinson’s diseases. Six ...
... at UCLA had found out the peptides that ward ... more than 20 years ago at UCLA, defensins are ... ward off viruses. However, it was unclear how defensins ... a specific defensin called retrocyclin-2 (RC2) binds to carbohydrate-containing ...
... no sunscreen in spite of staying under direct sunlight for ... spend a significant amount of time practicing and competing in ... are spending so much time in the sun, they have ... them regularly use any form of sunscreen, according to a ...
... that are difficult to handle. Even when so much has ... viral infection has always been a problem. Viral infections ... the disease-causing virus has always been potent enough to escape ... Human Immunodeficiency Virus as it is called has been posing ...
... Immunization (IFFIm) will be providing life saving vaccines for ... project costing $4 billion to be funded by the ... the scheme, the International Finance Facility for Immunization (IFF), ... over the next 10 years and another five million ...
... and Rabia Khatoon's joy knew no bounds when they got ... to pay for the surgery to separate their conjoined twins.// ... thousands of miles away has offered to help us,' Khatoon, ... even as the children get medical attention at New Delhi's ...
Cached Medicine News:Health News:Nanotechnology Revolution To Be Spearheaded By European Union 2Health News:People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings 2Health News:European Countries To Fund $4 Billion For Vaccination For Poor Children’ 2Health News:When A Prince Chose To Help Indian Couple 2
(Date:1/23/2015)... baseball,s all-time hits leader, is the new spokesperson for the ... has announced. "Pete,s a Hall of Famer in ... board with Myoflex," said Ducere Pharma Chief Executive Officer ... known across all generations. The passion and intensity that Pete ...
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... DURECT Corporation (Nasdaq: DRRX ) announced today that it has secured a ... million of its registered common stock to Azimuth Opportunity Ltd. for a ... $50 million facility.  DURECT did not pay a commitment fee or ... , , ...
... WASHINGTON , July 1 Hanger Orthopedic ... efforts in response to the January 12th ... alliance of U.S.-based international development and humanitarian nongovernmental organizations. ... Orthopedic Group was nominated by Physicians for Peace, an ...
Cached Medicine Technology:DURECT Corporation Secures $50 Million Committed Equity Financing Facility 2DURECT Corporation Secures $50 Million Committed Equity Financing Facility 3Hanger Orthopedic Group Honored for its Charitable Relief Efforts in Haiti by InterAction 2Hanger Orthopedic Group Honored for its Charitable Relief Efforts in Haiti by InterAction 3
... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
... Guidants 20-year history, the VOYAGER RX Dilatation ... treatment outcomes. It combines a new low ... profile shaft,more flexible markers, and short taper ... and tortuous anatomy with even greater confidence, ...
... Coat-A-Count AFP IRMA,is an ... measurement of,alpha-fetoprotein (AFP) in serum. ... vitro use in either of,two ... aid in the,management of patients ...
Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
Medicine Products: